Letter to the editorSiglec-7 is an inhibitory receptor on human mast cells and basophils
References (10)
- et al.
Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes
J Biol Chem
(1999) - et al.
The inhibitory receptor IRp60 (CD300a) suppresses the effects of IL-5, GM-CSF, and eotaxin on human peripheral blood eosinophils
Blood
(2006) - et al.
A small region of the natural killer cell receptor, Siglec-7, is responsible for its preferred binding to alpha 2,8-disialyl and branched alpha 2,6-sialyl residues: a comparison with Siglec-9
J Biol Chem
(2002) - et al.
SOCS3 targets Siglec 7 for proteasomal degradation and blocks Siglec 7-mediated responses
J Biol Chem
(2007) - et al.
Down-regulation of mast cell responses through ITIM containing inhibitory receptors
Adv Exp Med Biol
(2011)
Cited by (67)
Siglecs as potential targets of therapy in human mast cell- and/or eosinophil-associated diseases
2023, Seminars in ImmunologySiglec-9 is an inhibitory receptor on human mast cells in vitro
2023, Journal of Allergy and Clinical ImmunologyResearch Advances in Mast Cell Biology and Their Translation Into Novel Therapies for Anaphylaxis
2023, Journal of Allergy and Clinical Immunology: In PracticeRoles of Siglecs in neurodegenerative diseases
2023, Molecular Aspects of MedicineRole of Siglecs in viral infections: A double-edged sword interaction
2023, Molecular Aspects of MedicineSiglecs in allergy and asthma
2023, Molecular Aspects of Medicine
The authors acknowledge financial support for this study from a “Kamin” grant of the Israel Ministry of Industry and Trade (Grant no. 46223) and The Aimwell Charitable Trust Foundation (UK) to F.L.-S.; European Cooperation in Science and Technology COST Action BM1007 “Mast Cells and Basophils - Targets for Innovative Therapies” facilitated the collaboration between F.L.-S. and B.F.G. in support of this study. F.L.-S. is a member of the Dr Adolph and Klara Brettler Center for Research in Molecular Pharmacology and Therapeutics and the David R. Bloom Center for Pharmacy at The Hebrew University of Jerusalem's School of Pharmacy.
Disclosure of potential conflict of interest: S. Mizrahi has received travel support from the European Cooperation in Science and Technology COST Action BM1007. B. F. Gibbs has received start-up funds from and is employed by the University of Kent, has received payment for lectures from the University of Virgina and ALK Abello, and has received travel support from EU/ESF COST Action BM1007. F. Levi-Schaffer has received research support from the Israeli Ministry of Industry and Trade (Grant No. 46223); is a member of the Committee for Human Experimentation of New Drugs for the Israeli Ministry of Health; and has received travel support from EU/ESF COST Action BM1007. The rest of the authors declare that they have no relevant conflicts of interest.
- ∗
These authors contributed equally to this work.